These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16443870)

  • 1. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.
    Huang ES; Shook M; Jin L; Chin MH; Meltzer DO
    Diabetes Care; 2006 Feb; 29(2):259-64. PubMed ID: 16443870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia.
    Eastman RC; Javitt JC; Herman WH; Dasbach EJ; Copley-Merriman C; Maier W; Dong F; Manninen D; Zbrozek AS; Kotsanos J; Garfield SA; Harris M
    Diabetes Care; 1997 May; 20(5):735-44. PubMed ID: 9135935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.
    Wake N; Hisashige A; Katayama T; Kishikawa H; Ohkubo Y; Sakai M; Araki E; Shichiri M
    Diabetes Res Clin Pract; 2000 Jun; 48(3):201-10. PubMed ID: 10802159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X; Vondeling H
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.
    Cleveringa FG; Welsing PM; van den Donk M; Gorter KJ; Niessen LW; Rutten GE; Redekop WK
    Diabetes Care; 2010 Feb; 33(2):258-63. PubMed ID: 19933991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis.
    Gu S; Shi L; Shao H; Wang X; Hu X; Gu Y; Dong H
    BMC Med; 2020 Dec; 18(1):378. PubMed ID: 33267884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
    Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
    Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
    Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
    J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
    Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
    Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
    Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
    Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life.
    Wu SY; Sainfort F; Tomar RH; Tollios JL; Fryback DG; Klein R; Klein BE
    Diabetes Care; 1998 May; 21(5):725-31. PubMed ID: 9589231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.
    Gray A; Raikou M; McGuire A; Fenn P; Stevens R; Cull C; Stratton I; Adler A; Holman R; Turner R
    BMJ; 2000 May; 320(7246):1373-8. PubMed ID: 10818026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.